Buy APLS near 28.9 target 36.47 stop loss @ 28.82 Details The technical summary data tells us to buy APLS near 28.9 with an ...

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BofA lowered the firm’s price target on Apellis (APLS) to $47 from $61 and keeps a Buy rating on the shares after the company reported Q3 Syfovre revenues that came in below expectations. The firm ...

Investing.com - Apellis Pharma (NASDAQ: APLS) reported second quarter EPS of $-0.30, $0.01 better than the analyst estimate of $-0.31. Revenue for the quarter came in at $179.14M ...

Republican state lawmakers are already poised to pass legislation that will allow for the prosecution of librarians.

WALTHAM, Mass. - Apellis Pharmaceuticals, Inc. (NASDAQ: NASDAQ:APLS) has secured a senior secured credit facility of up to $475 million with global investment firm Sixth Street,... ByInvesting.com ...